Tema Etfs LLC Has $4.19 Million Stake in Boston Scientific Corporation $BSX

Tema Etfs LLC raised its stake in Boston Scientific Corporation (NYSE:BSX) by 148.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,950 shares of the medical equipment provider’s stock after acquiring an additional 25,641 shares during the quarter. Tema Etfs LLC’s holdings in Boston Scientific were worth $4,193,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Boston Scientific by 136.7% during the first quarter. Geneos Wealth Management Inc. now owns 3,423 shares of the medical equipment provider’s stock worth $345,000 after buying an additional 1,977 shares in the last quarter. Advisors Capital Management LLC increased its holdings in shares of Boston Scientific by 27.5% during the first quarter. Advisors Capital Management LLC now owns 4,400 shares of the medical equipment provider’s stock worth $444,000 after buying an additional 948 shares in the last quarter. Modern Wealth Management LLC lifted its stake in shares of Boston Scientific by 7.9% in the 1st quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider’s stock valued at $300,000 after acquiring an additional 218 shares during the last quarter. Finally, Kera Capital Partners Inc. acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $354,000. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Canaccord Genuity Group reduced their price target on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a report on Friday, October 17th. Evercore ISI set a $112.00 target price on shares of Boston Scientific in a research report on Monday, January 5th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $112.00 price target on shares of Boston Scientific in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $125.21.

Boston Scientific Stock Down 0.7%

Shares of NYSE BSX opened at $97.68 on Monday. The company’s 50 day moving average price is $97.58 and its 200-day moving average price is $100.73. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a market capitalization of $144.80 billion, a P/E ratio of 52.23, a price-to-earnings-growth ratio of 1.73 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the company posted $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 93,095 shares of company stock valued at $9,305,450. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.